-
Je něco špatně v tomto záznamu ?
Neudesin in obesity and type 2 diabetes mellitus: the effect of acute fasting and weight reducing interventions
H. Kratochvilova, Z. Lacinova, J. Klouckova, P. Kavalkova, A. Cinkajzlova, P. Trachta, J. Krizova, M. Benes, K. Dolezalova, M. Fried, Z. Vlasakova, T. Pelikanova, J. Spicak, M. Mraz, M. Haluzik,
Jazyk angličtina
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2008
Free Medical Journals
od 2008
PubMed Central
od 2008
Europe PubMed Central
od 2008
ProQuest Central
od 2008-01-01
Open Access Digital Library
od 2008-01-01
Open Access Digital Library
od 2008-01-01
Taylor & Francis Open Access
od 2008-10-01
Nursing & Allied Health Database (ProQuest)
od 2008-01-01
Public Health Database (ProQuest)
od 2008-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2008
PubMed
30992678
DOI
10.2147/dmso.s193259
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Context: Neudesin has recently been identified as a novel regulator of energy expenditure in experimental animals; however, its role in humans remains unexplored. Objective: The aim of this study was to assess the effects of obesity and type 2 diabetes mellitus (T2DM) along with selected weight reducing interventions on serum neudesin levels and adipose tissue mRNA expression. Patients and methods: Fifteen obese subjects with T2DM undergoing endoscopic duodenal-jejunal bypass liner (DJBL) implantation, 17 obese subjects (11 with T2DM, 6 without T2DM) scheduled for gastric plication (GP), 15 subjects with functional hypoglycemia subjected to 72-hour acute fasting (AF), and 12 healthy controls were included in the study. Results: Baseline neudesin levels were comparable between all groups. DJBL increased neudesin at 6 and 10 months after the procedure (1.77±0.86 vs 2.28±1.27 vs 2.13±1.02 ng/mL, P=0.001 for baseline vs 6 vs 10 months) along with reduction in body weight and improvement of HbA1c without any effect on neudesin mRNA expression in subcutaneous adipose tissue. Conversely, GP did not affect neudesin levels despite marked reduction in body weight and improvement of HbA1c. In contrast, AF decreased neudesin levels during the entire period (1.74±0.54 vs 1.46±0.48 ng/mL, P=0.001 for baseline vs 72 hours) with no impact of subsequent re-alimentation on neudesin concentrations. Conclusion: Neudesin levels are differentially regulated during AF and chronic weight reduction induced by DJBL or GP. Further studies are needed to assess its possible significance in energy homeostasis regulation in humans.
Department of Surgery OB Clinic Prague Czech Republic
Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19029137
- 003
- CZ-PrNML
- 005
- 20190822130322.0
- 007
- ta
- 008
- 190813s2019 New f 000 0| 000
- 009
- AR
- 024 7_
- $a 10.2147/DMSO.S193259 $2 doi
- 035 __
- $a (PubMed)30992678
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a New Zealand
- 100 1_
- $a Kratochvilova, Helena $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, martin.haluzik@ikem.cz. Department of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic, martin.haluzik@ikem.cz. Department of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Prague, Czech Republic, martin.haluzik@ikem.cz.
- 245 10
- $a Neudesin in obesity and type 2 diabetes mellitus: the effect of acute fasting and weight reducing interventions / $c H. Kratochvilova, Z. Lacinova, J. Klouckova, P. Kavalkova, A. Cinkajzlova, P. Trachta, J. Krizova, M. Benes, K. Dolezalova, M. Fried, Z. Vlasakova, T. Pelikanova, J. Spicak, M. Mraz, M. Haluzik,
- 520 9_
- $a Context: Neudesin has recently been identified as a novel regulator of energy expenditure in experimental animals; however, its role in humans remains unexplored. Objective: The aim of this study was to assess the effects of obesity and type 2 diabetes mellitus (T2DM) along with selected weight reducing interventions on serum neudesin levels and adipose tissue mRNA expression. Patients and methods: Fifteen obese subjects with T2DM undergoing endoscopic duodenal-jejunal bypass liner (DJBL) implantation, 17 obese subjects (11 with T2DM, 6 without T2DM) scheduled for gastric plication (GP), 15 subjects with functional hypoglycemia subjected to 72-hour acute fasting (AF), and 12 healthy controls were included in the study. Results: Baseline neudesin levels were comparable between all groups. DJBL increased neudesin at 6 and 10 months after the procedure (1.77±0.86 vs 2.28±1.27 vs 2.13±1.02 ng/mL, P=0.001 for baseline vs 6 vs 10 months) along with reduction in body weight and improvement of HbA1c without any effect on neudesin mRNA expression in subcutaneous adipose tissue. Conversely, GP did not affect neudesin levels despite marked reduction in body weight and improvement of HbA1c. In contrast, AF decreased neudesin levels during the entire period (1.74±0.54 vs 1.46±0.48 ng/mL, P=0.001 for baseline vs 72 hours) with no impact of subsequent re-alimentation on neudesin concentrations. Conclusion: Neudesin levels are differentially regulated during AF and chronic weight reduction induced by DJBL or GP. Further studies are needed to assess its possible significance in energy homeostasis regulation in humans.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lacinova, Zdenka $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, martin.haluzik@ikem.cz. Department of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic, martin.haluzik@ikem.cz. Department of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Prague, Czech Republic, martin.haluzik@ikem.cz.
- 700 1_
- $a Klouckova, Jana $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, martin.haluzik@ikem.cz. Department of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic, martin.haluzik@ikem.cz. Department of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Prague, Czech Republic, martin.haluzik@ikem.cz.
- 700 1_
- $a Kavalkova, Petra $u Department of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic, martin.haluzik@ikem.cz. Department of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Prague, Czech Republic, martin.haluzik@ikem.cz.
- 700 1_
- $a Cinkajzlova, Anna $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, martin.haluzik@ikem.cz. Department of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic, martin.haluzik@ikem.cz. Department of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Prague, Czech Republic, martin.haluzik@ikem.cz.
- 700 1_
- $a Trachta, Pavel $u Third Department of Medicine, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Krizova, Jarmila $u Third Department of Medicine, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Benes, Marek $u Hepatogastroenterology Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Dolezalova, Karin $u Department of Surgery, OB Clinic, Prague, Czech Republic.
- 700 1_
- $a Fried, Martin $u Department of Surgery, OB Clinic, Prague, Czech Republic.
- 700 1_
- $a Vlasakova, Zuzana $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, martin.haluzik@ikem.cz.
- 700 1_
- $a Pelikanova, Terezie $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, martin.haluzik@ikem.cz.
- 700 1_
- $a Spicak, Julius $u Hepatogastroenterology Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Mraz, Milos $u Department of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic, martin.haluzik@ikem.cz. Department of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Prague, Czech Republic, martin.haluzik@ikem.cz. Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, martin.haluzik@ikem.cz.
- 700 1_
- $a Haluzik, Martin $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, martin.haluzik@ikem.cz. Department of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic, martin.haluzik@ikem.cz. Department of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Prague, Czech Republic, martin.haluzik@ikem.cz. Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, martin.haluzik@ikem.cz.
- 773 0_
- $w MED00173678 $t Diabetes, metabolic syndrome and obesity : targets and therapy $x 1178-7007 $g Roč. 12, č. - (2019), s. 423-430
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30992678 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190822130600 $b ABA008
- 999 __
- $a ind $b bmc $g 1434286 $s 1067597
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 12 $c - $d 423-430 $e 20190328 $i 1178-7007 $m Diabetes, metabolic syndrome and obesity $n Diabetes metab. syndr. obes. $x MED00173678
- LZP __
- $a Pubmed-20190813
